About the equivalence between different batches of a glycopeptide drug-Reference-Cited by-同舟云学术

About the equivalence between different batches of a glycopeptide drug

Published:2015-04-17 Issue:5 Volume:21 Page:642-645
ISSN:1083-7450
Container-title:Pharmaceutical Development and Technology
language:en
Short-container-title:Pharmaceutical Development and Technology

Author:

Boix-Montañes Antonio¹,Garcia-Arieta Alfredo²

Affiliation:

1. Departamento de Farmacia y Tecnologia Farmacéutica, Facultad de Farmacia/Universidad de Barcelona, Barcelona, Spain and

2. División de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/10837450.2015.1035726

Reference15 articles.

1. Pharmacokinetics of individual components of teicoplanin in man

2. Clinical Pharmacokinetics of Teicoplanin

3. European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr. 2010 Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientificguideline/2010/01/WC500070039.pdf [last accessed 13 Jun 2014]

4. European Medicines Agency. Questions and answers on the referral for teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin. EMA/CHMP/77992/2010. EMEA/H/A-29/1084. 2009. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/Referrals_document/Teicoplanin_Hospira_29/WC500014116.pdf [last accessed 17 Feb 2013]

5. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus